「GLP-1」のタグが付いた記事一覧
CMSは、保険プラン側が現時点では参加準備が整っていないと示したことを受け、肥満治療薬の補償に焦点を当てたメディケアのパイロットを無期限に延期した。
ノボ ノルディスクは、GLP-1の先駆者ロッテ・ビエレ・クヌーセンの退任と、肥満分野のリーダーのベーリンガーインゲルハイムへの移籍という、2つの人事変動に同時に対応しています。
23andMe Research Institute が発表した研究では、GLP-1 の減量効果と副作用の両方に関連する遺伝的予測因子が特定され、より個別化された肥満治療への可能性が示された。
Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.
Structure Therapeuticsは、その経口GLP-1受容体作動薬の励みになる第2相の結果を報告し、注射剤型の減量および糖尿病薬の代替丸剤形式を推し進めています。
After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.
Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.
Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.
Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.
With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.
